|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of the American College of Cardiology|
|State||Published - Apr 29 2014|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
In: Journal of the American College of Cardiology, Vol. 63, No. 16, 29.04.2014, p. 1700-1702.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention
AU - Wang, Tracy Y.
AU - McCoy, Lisa
AU - Henry, Timothy D.
AU - Effron, Mark B.
AU - Messenger, John C.
AU - Cohen, David J.
AU - Mark, Daniel B.
AU - Stone, Gregg W.
AU - Zettler, Marjorie
AU - Singh, Mandeep
AU - Fonarow, Gregg C.
AU - Peterson, Eric D.
N1 - Funding Information: Please note: The TRANSLATE-ACS study ( NCT01088503 ) is sponsored by Daiichi Sankyo and Lilly USA. The Duke Clinical Research Institute is the coordinating center for this study, which represents a collaborative effort with the American College of Cardiology. The authors thank Erin Hanley, MS, for her editorial contributions to this paper. Ms. Hanley did not receive compensation for her assistance, apart from her employment at the institution where this study was conducted. Dr. Wang has received research grant support (to institution) from Eli Lilly, Daiichi Sankyo, Gilead Sciences, GlaxoSmithKline, American College of Cardiology, and American Society of Nuclear Cardiology (all significant); and educational activities or lectures for AstraZeneca and the American College of Cardiology (both modest). Dr. Effron is an employee of Eli Lilly; and a shareholder of Lilly, USA. Dr. Cohen has received consulting services for Eli Lilly, Daiichi Sankyo, and AstraZeneca; and research grant support (to institution) for Eli Lilly and AstraZeneca. Dr. Mark has received research funding from Eli Lilly and Medtronic (significant). Dr. Stone is a consultant to Boston Scientific, Eli Lilly, Daiichi Sankyo, and AstraZeneca (all modest). Dr. Zettler is an employee of Eli Lilly. Dr. Fonarow is a consultant to Novartis (significant) and Janssen (modest). Dr. Peterson has received research funding for the American College of Cardiology, American Heart Association, Eli Lilly, Janssen, and Society of Thoracic Surgeons (all significant); and consulting (including continuing medical education) for Merck (modest), Boehringer Ingelheim, Genentech, Janssen, and Sanofi-Aventis (all significant). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2014/4/29
Y1 - 2014/4/29
UR - http://www.scopus.com/inward/record.url?scp=84898939004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898939004&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2013.12.012
DO - 10.1016/j.jacc.2013.12.012
M3 - Letter
C2 - 24486275
AN - SCOPUS:84898939004
SN - 0735-1097
VL - 63
SP - 1700
EP - 1702
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 16